Melbourne, Aug 13, 2008 (ABN Newswire) - Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced the start of its next clinical trial of VivaGel(R). The study will measure the level of antiviral activity retained by VivaGel(R) after vaginal administration. Assessment will be by laboratory assay of vaginal samples collected up to 24 hours after VivaGel(R) application. The study in 12 women will determine the timescale over which VivaGel(R) retains activity against HIV and HSV-2 (genital herpes).
